Polypharmacy (>=5Rx) studied in 81 RA & 30 SLE pts. Polypharmacy incr at 2 yrs ~44% to ~73%. Med adherence >85%. Polypharmacy NOT assoc w/ Dz activity in SLE, but in RA did correlate w/ better DAS28CRP score at one year https://t.co/Jw05DIrBym https://t.co/pLIoDvPj8i

Metanalysis of 376 studies, 347 468 pts w/ chronic pain (mean 51yrs; 70%F) finds ~40% had clinically significant depression and anxiety (more common in Women, younger people, pts w nociplastic pain). Depression common in FM (54%) & OA/RA (~28%). https://t.co/s1tcgC3y7k https://t.co/NCxkOA82jD

MMWR: Idiopathic Pulmonary Fibrosis Mortality in the United States Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and worsening lung function, has a poor prognosis. An estimated 21% of IPF deaths might be attributable to occupational… https://t.co/FQpotKrgzR https://t.co/hruzwcD1E6

ED Utilization by Psoriatic and Spondyloarthritis Patients A cohort analysis of ambulatory ED utilization by patients with PsA and r-axSpA demonstrated significant use for less urgent and nonurgent health issues, particularly in rural settings. https://t.co/Pl9k3GN0mp https://t.co/kI1rOue9ws

Intraarticular Steroids in OA Lowers Need for Pain Meds Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids? https://t.co/qkTN7CpuMZ https://t.co/npuT88Sj2m

Hydroxychloroquine and Sjögren's - despite widespread use, there is not good data showing HCQ efficacy in Sjogrens. Although safe and may lower Ig levels - 3 RCTs found no clinical benefit, but retrospective & open-label studies did https://t.co/8l1gZoKqFA https://t.co/JNGmpnNMHx

Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/evsvf2GQiL https://t.co/J0Zl35FEHz

Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/N7XVbfnsfi https://t.co/yjKwcfugOJ

Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/N4u4AUbdqH https://t.co/PotKfpOkH7

Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/MHFUWb3az1 https://t.co/cqzZG40Xp5